Business Context and Reporting Period
This Form 6-K filing by BioLineRx Ltd. covers the month of August 2026. The Company, an Israeli foreign private issuer, announced a registered direct offering and concurrent private placement of securities to raise capital for research and development and working capital purposes.
Key Financial Metrics and Capital Structure
- Aggregate Gross Proceeds: Approximately $3,750,000 (assuming full exercise of Pre-funded Warrants and no exercise of Warrants).
- Offering Price: $2.78 per ADS and accompanying Warrant; $2.7799 per Pre-funded Warrant and accompanying Warrant.
- Securities Issued:
- 480,696 American Depositary Shares (ADSs).
- Pre-funded Warrants to purchase up to 868,225 ADSs (exercise price $0.001).
- Unregistered Warrants to purchase up to 2,023,382 ADSs (exercise price $2.78, 5-year term).
- Transaction Costs: 7.0% cash placement fee, 1.0% management fee, and up to $50,000 for accountable expenses.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for current period revenue, profit, operating cash flow, or specific debt levels.
Material Changes and Transactions
The primary material change is the execution of a Securities Purchase Agreement on August 27, 2026, to raise approximately $3.75 million. Additionally, the Company amended existing warrants held by the purchaser to reduce the exercise price to $2.78 per ADS and extend the term to August 31, 2031. The Company is subject to a 120-day lock-up on variable rate transactions and a 60-day standstill restriction following the closing date.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Net proceeds are intended for research and development activities, working capital, and general corporate purposes.
- Closing Date: Expected on or about August 31, 2026, subject to customary closing conditions.
- Risks and Contingencies: The filing includes a warning that the Offering may not close if conditions are not satisfied. Forward-looking statements regarding the closing date are not guaranteed.
- Ownership Restrictions: Beneficial ownership limitations apply, capping exercise rights if a holder would own more than 4.99% (or 9.99% at election) of outstanding Ordinary Shares.
Investor Verification Checklist
- Verify the actual closing date of the Offering and whether all customary conditions were satisfied.
- Confirm the final net proceeds after deducting the 8% total fees (placement and management) and expenses.
- Review the impact of the new warrant issuance and the amendment of existing warrants on potential future dilution.
- Monitor the Company's cash runway and burn rate given the stated intent to fund R&D and working capital.
- Check for any subsequent filings regarding the exercise of Pre-funded Warrants or changes in the 120-day variable rate transaction restriction.